Wegovy Neck: Sagging & Turkey Neck After Semaglutide

“Wegovy neck” is the social-media name for the loose, crepey, sagging skin and lost fullness under the chin, along the jawline, and down the neck after fast weight loss on Wegovy. Wegovy is semaglutide dosed at 2.4 mg — the obesity brand of the same GLP-1 receptor agonist molecule sold for type 2 diabetes as Ozempic. It is not a toxic effect of semaglutide on the neck. It is the cosmetic consequence of rapid fat loss: the subcutaneous fat under the chin and jaw (the submental fat pad) shrinks, a share of the weight lost is lean (muscle) mass, and the skin that was stretched over a previously fuller neck no longer has the volume to fill it — so it drapes, revealing jowls, vertical neck bands (platysmal bands), and what people call a “turkey neck.” What makes Wegovy notable is the dose: at 2.4 mg, semaglutide drives substantial weight loss — about −14.9% of body weight at week 68 in the STEP 1 pivotal trial (Wilding 2021^[1]) — so neck changes are commonly noticed. This is the neck counterpart to “Ozempic face,” and because it shares its mechanism exactly, our “Ozempic neck” article covers the same physiology in depth. This piece focuses on the Wegovy angle.

What "Wegovy neck" actually is

“Wegovy neck” is a colloquial, not a medical, term. It describes the under-chin and neck area looking looser, saggier, more crepey, or more lined after substantial weight loss on Wegovy (semaglutide 2.4 mg). People notice loss of the smooth, full contour under the jaw, a softer or more wrinkled neck, more visible jowls at the jawline, vertical cords running down the front of the neck, and the characteristic loose fold sometimes called a “turkey neck.”

The crucial point is that this is not a drug toxicity aimed at the neck. Semaglutide has no known pharmacological action on neck skin or the submental fat pad. It is the same phenomenon described for decades after bariatric surgery, anorexia nervosa, and aggressive medical weight loss. Wegovy draws attention only because it reliably produces large, rapid weight loss — semaglutide 2.4 mg averaged about −14.9% body weight over 68 weeks in STEP 1 (Wilding 2021^[1]) — so the change is bigger and faster, and therefore more visible. It is the same molecule as Ozempic, simply at the higher obesity dose, which is why the neck effect is the same as “Ozempic neck.”

Why it happens — fat loss, skin laxity, and aging anatomy

1. Submental and neck fat shrinks

The smooth, full contour under the chin and along the jawline depends in large part on the submental fat pad and the subcutaneous fat of the neck. This subcutaneous fat is exactly the kind that a sustained caloric deficit mobilizes — subcutaneous depots shrink along with the rest of the body's fat stores during weight loss (Manolopoulos 2010^[2]). The face-and-neck region is rich in superficial fat compartments that deflate first: the imaging cohort that put the first hard number on “Ozempic face” found a median 9% loss of total midfacial volume on a GLP-1, and the loss tracked with kilograms lost rather than with the drug or dose (Sharma 2025^[3]). The submental fat under the chin behaves the same way. Less fat under the jaw means a sharper but also emptier contour — and an empty contour is what allows the skin above it to fall. On Wegovy, where the 2.4 mg obesity dose drives substantial total loss, there is simply more fat coming off the neck than on lower-efficacy regimens.

2. Skin that was stretched now drapes

Skin stretched over a larger volume for a long time does not always retract fully when the underlying fat disappears — especially with faster loss, larger total loss, older age, sun damage, and genetics. Histology from massive-weight-loss patients makes the mechanism concrete: after major loss, skin biopsies showed increased fibrosis and a measurable decrease in dermal collagen and elastic fibres, which became disorganized (Cálix 2024^[4]). Less elastic recoil in the dermis is precisely why the neck skin sags rather than snapping back. The result is laxity — crepey, loose, lined, or hanging skin under the chin and down the neck. This is the same mechanism behind loose skin elsewhere on the body after weight loss.

3. The neck was already aging underneath

Rapid fat loss often simply reveals aging that was already underway. Skin senescence — the age-related decline in collagen and elastic-fibre quality — produces laxity, crepiness, and wrinkles independent of weight (Dorf 2024^[5]). The neck's vertical bands are the platysma muscle, a thin sheet that runs up the neck; with age it loosens and its discernible insertion drops, contributing to visible cords and jowls (Kildal 2025^[6]). When a fuller neck masked these changes, losing the fat that was hiding them can make the neck look suddenly older — the fat had been acting as a soft-tissue filler.

Put the three together — less fat, looser skin, and previously hidden aging — and you get the characteristic saggy, banded, “turkey neck” look. The fat loss is mostly the desired result of the weight loss; the skin laxity and revealed aging are the parts worth actively managing.

Why Wegovy specifically? It is high-dose semaglutide

Wegovy and Ozempic are the same molecule — semaglutide — sold under different brand names for different indications. Ozempic is approved for type 2 diabetes and titrates to 1.0–2.0 mg; Wegovy is approved for weight management and titrates to the higher 2.4 mg obesity dose. That higher dose is engineered to produce more weight loss, and it does: about −14.9% of body weight at week 68 in STEP 1 (Wilding 2021^[1]). Because the neck change scales with how many kilograms come off, the substantial loss Wegovy delivers means neck changes are commonly noticed — more so than with the lower diabetes dosing. The neck effect is not unique to Wegovy or to semaglutide; it appears with every route to fast, large weight loss. Wegovy is simply a common cause because it is widely prescribed specifically to drive obesity-level weight loss.

Before and after — what to expect, and is it permanent?

“Wegovy neck” before-and-after photos circulate widely, but the honest picture is more nuanced than the dramatic comparisons suggest. A few patterns hold:

• It scales with how much and how fast. The larger the total weight loss and the faster it happens, the more pronounced the neck change — because the facial-and-neck volume change tracks with kilograms lost (Sharma 2025^[3]), and Wegovy's 2.4 mg dose drives substantial loss.
• Age and skin quality dominate the outcome. Younger skin with intact collagen and elastin retracts far better; older, sun-damaged, or previously stretched skin retracts less (Dorf 2024^[5], Cálix 2024^[4]).
• The fat loss is largely permanent — and intended. The submental fat does not come back unless weight is regained, which is not the goal.
• The skin laxity is partly, not fully, reversible. Mild laxity often improves over months as weight stabilizes and skin slowly retracts; significant loose skin (a true “turkey neck”) may not fully self-correct and is where elective options come in.

So the realistic before-and-after is: a sharper but emptier jawline and neck, with skin that ranges from barely-changed (younger, slower loss) to noticeably loose (older, larger, faster loss). The fat side is permanent; the skin side improves partially on its own and further with intervention.

Why a thinner neck can look older

This is the counterintuitive part. People expect weight loss to make them look younger, and on the body it often does — but in the face and neck, subcutaneous fat is part of what reads as “youthful.” A full neck and jawline hides the underlying platysmal bands, the jowls, and the crepey skin that accumulate with age. When fat is the soft-tissue scaffolding holding skin smooth, removing it lets the skin settle onto the now-aged framework underneath (Dorf 2024^[5], Kildal 2025^[6]). The same total weight lost slowly over years — via lifestyle change — produces the same fat loss but gives skin more time to adapt, which is why the rapid trajectory of Wegovy makes the effect more obvious. None of this means the weight loss is harming the neck; it means the cosmetic trade-off of fast facial-and-neck fat loss is real and worth planning around.

How to avoid or reduce "Wegovy neck"

Lose gradually and protect the foundation (prevention)

The most useful interventions happen during the loss, not after. Because the neck change tracks with the rate and total amount of weight lost, a slower, steadier trajectory gives skin more time to retract. Three measures have reasonable support:

1. Slower titration where appropriate. Wegovy is titrated upward over months toward the 2.4 mg target. Discuss with your prescriber whether extending each dose step reduces your rate of loss; a slower rate gives the dermis more time to adapt and reduces the abruptness of the neck change.
2. Adequate protein and resistance training to preserve lean mass. Protein around 1.2–1.6 g/kg per day plus resistance training preserves the lean-mass and structural framework of the face and neck; resistance training during caloric restriction largely prevented the lean-mass loss otherwise seen with diet alone (Sardeli 2018^[7]), and higher protein in a deficit protects fat-free mass (Longland 2016^[8]). It matters because a meaningful share of GLP-1 weight loss is lean tissue by default — roughly 20–30% of weight lost across modalities (Cava 2017^[9]). Our GLP-1 muscle-loss prevention protocol covers this in full. This does not stop fat loss in the neck, but it preserves the underlying support.
3. Protect the skin itself. Reaching and holding a stable weight, staying hydrated, not smoking, and daily sun protection all support the collagen and elastin that determine how well neck skin retracts (Dorf 2024^[5]).

Skincare and the limits of topicals

Topical skincare — retinoids, peptides, sunscreen, and moisturizers — supports skin quality and can modestly improve crepiness and fine lines over time, but it cannot meaningfully tighten established, significant laxity. For mild “Wegovy neck” it is a reasonable foundation; for a true sagging “turkey neck,” expectations should be realistic, and energy-based or surgical options carry the stronger evidence.

Non-surgical skin tightening

Energy-based devices are the main non-surgical route for neck laxity. Radiofrequency and ultrasound-based skin-tightening work by heating the dermis to stimulate fibroblasts — the cells that produce collagen, elastic fibres, and hyaluronic acid, whose activity declines with age. A 2025 evaluation of monopolar radiofrequency documented fibroblast stimulation and restoration of the dermal matrix as the mechanism behind improvement in skin laxity (Goldman 2025^[10]). These treatments are best suited to mild-to-moderate laxity, typically require a series of sessions, and produce gradual rather than dramatic tightening; they do not remove substantial excess skin.

Reducing residual submental fullness

Less commonly with “Wegovy neck” — since the problem is usually too little fat — some people retain a pocket of stubborn submental fat under loose skin. Injectable deoxycholic acid is FDA-approved for reducing submental fat: in one before-and-after study, monthly injections produced at least a one-grade improvement on a validated submental-fat scale in roughly two-thirds to four-fifths of patients, with a significant decrease in submental-fat thickness and mild, temporary side effects (Yazdanparast 2025^[11]). It reduces fat, however — it does not tighten skin, and on an already-deflated neck it can worsen the appearance of laxity, so it is used selectively.

Surgical options (elective)

For significant skin excess and banding that does not respond to energy devices, surgical neck lift and platysmaplasty (tightening the platysma muscle and removing excess skin) are the definitive option — the same family of body-contouring procedures used after major weight loss to address excess skin (Sadeghi 2022^[12]). These are elective, carry surgical cost and risk, and are described here neutrally, not recommended. As with “Ozempic face,” the practical advice is to time any cosmetic intervention after weight has stabilized for a few months, because treating before the target weight is reached produces mismatches that need re-treatment as more weight comes off — a particular consideration on Wegovy, whose titration and weight-loss phase runs many months.

"Turkey neck" specifically — what it is and what helps

“Turkey neck” is the vivid term for loose, hanging skin and visible vertical cords under the chin, named for the resemblance to a turkey's wattle. Anatomically it combines three things: loose, low-elasticity skin; loss of the submental fat that kept the contour smooth; and prominent platysmal bands — the edges of the platysma muscle that become more visible as the neck loosens and the muscle's position shifts with age (Kildal 2025^[6]). Because it is partly skin and partly muscle, topicals and skincare do little for an established turkey neck. Energy-based tightening can help mild cases (Goldman 2025^[10]); the prominent bands and significant excess skin of a true turkey neck are most reliably addressed surgically with neck lift and platysmaplasty (Sadeghi 2022^[12]). Reaching a stable weight first is important, because further weight loss changes the result.

When it is a body-image concern, not just a cosmetic one

Rapid changes in appearance can be psychologically complex even when the weight loss is wanted. Some people are distressed that their face and neck look older, or find that reaching a goal weight did not resolve dissatisfaction the way they expected. If preoccupation with the neck or appearance becomes distressing, intrusive, or starts driving restrictive behavior, that is worth raising with a clinician — our guide on body image, disclosure, and post-loss grief on a GLP-1 covers this in depth. “Wegovy neck” is a real and common cosmetic effect, and it is also partly addressable — framing it accurately helps keep it in proportion.

Bottom line

• “Wegovy neck” is the loose, crepey, sagging under-chin and neck skin seen after rapid weight loss on Wegovy (semaglutide 2.4 mg) — a fat-loss and skin-laxity effect, not a drug toxicity to the neck.
• Wegovy is the obesity-dose brand of semaglutide — the same molecule as Ozempic — so “Wegovy neck” is mechanistically identical to “Ozempic neck”: loss of submental and neck subcutaneous fat (facial-and-neck volume tracks with kilograms lost, ~9% midfacial loss in the imaging cohort^[3]) plus skin that no longer retracts over a smaller frame.
• It is commonly noticed because the 2.4 mg obesity dose drives substantial loss — about −14.9% of body weight at week 68 in STEP 1 (Wilding 2021^[1]).
• A thinner neck can look older because facial-and-neck fat hides aging skin, jowls, and platysmal bands; removing it reveals the aging underneath (Dorf 2024^[5], Kildal 2025^[6]).
• To reduce it: lose gradually, preserve lean mass with protein and resistance training (Sardeli 2018^[7]), protect skin, and let mild laxity self-correct over a few stable months.
• Elective options (neutral): non-surgical radiofrequency/ultrasound tightening for mild-to-moderate laxity (Goldman 2025^[10]), deoxycholic acid for residual submental fat (Yazdanparast 2025^[11]), and surgical neck lift/platysmaplasty for significant excess skin and “turkey neck” (Sadeghi 2022^[12]) — best timed after weight is stable.
• If the change becomes a source of significant distress, treat it as a body-image concern worth discussing with a clinician.

Related research

• Ozempic neck — the same neck mechanism on the diabetes-brand of semaglutide, with the full physiology and evidence.
• Ozempic face — the shared subcutaneous-fat-loss mechanism in the face, imaging-quantified (no separate Wegovy-face article; this covers the semaglutide case).
• Preventing muscle loss on a GLP-1 — the resistance-training and protein protocol that protects the neck-and-jaw foundation.
• How to tighten loose skin after weight loss — the body-wide guide to skin laxity and the evidence behind tightening.
• Body image, disclosure, and post-loss grief on a GLP-1 — for when appearance change becomes distressing.

Important disclaimer. This article is educational and does not constitute medical, dermatologic, or cosmetic-procedure advice. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management; the same molecule is approved for type 2 diabetes as Ozempic. Skin-tightening and surgical procedures are elective and carry their own risks; discuss them with a board-certified dermatologist or plastic surgeon. Protein targets assume normal renal function, and resistance-training programs should be individualized. Every primary source cited here was verified against the live PubMed E-utilities API on 2026-06-20.